JP2005508971A - 製剤 - Google Patents

製剤 Download PDF

Info

Publication number
JP2005508971A
JP2005508971A JP2003537610A JP2003537610A JP2005508971A JP 2005508971 A JP2005508971 A JP 2005508971A JP 2003537610 A JP2003537610 A JP 2003537610A JP 2003537610 A JP2003537610 A JP 2003537610A JP 2005508971 A JP2005508971 A JP 2005508971A
Authority
JP
Japan
Prior art keywords
granules
dry
tablet
effective amount
lubricant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003537610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508971A5 (enExample
Inventor
デ・マタス，マルセル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2005508971A publication Critical patent/JP2005508971A/ja
Publication of JP2005508971A5 publication Critical patent/JP2005508971A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2003537610A 2001-10-24 2002-10-23 製剤 Withdrawn JP2005508971A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0125492.9A GB0125492D0 (en) 2001-10-24 2001-10-24 Formulation
PCT/GB2002/004835 WO2003035043A2 (en) 2001-10-24 2002-10-23 Pharmaceutical formulation comprising more than 15% tamoxifen

Publications (2)

Publication Number Publication Date
JP2005508971A true JP2005508971A (ja) 2005-04-07
JP2005508971A5 JP2005508971A5 (enExample) 2006-01-05

Family

ID=9924411

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003537610A Withdrawn JP2005508971A (ja) 2001-10-24 2002-10-23 製剤

Country Status (6)

Country Link
US (1) US20050042279A1 (enExample)
EP (1) EP1448171A2 (enExample)
JP (1) JP2005508971A (enExample)
AU (1) AU2002341145A1 (enExample)
GB (1) GB0125492D0 (enExample)
WO (1) WO2003035043A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018536707A (ja) * 2015-10-30 2018-12-13 キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド エフロルニチンとスリンダクの固定用量複合製剤

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI547431B (zh) * 2004-06-09 2016-09-01 史密斯克萊美占公司 生產藥物之裝置及方法
CZ297446B6 (cs) * 2004-09-30 2006-12-13 Pliva - Lachema A. S. Zpusob prípravy orální pevné lékové formy a orální pevná léková forma pripravená tímto zpusobem
US10201549B2 (en) * 2013-06-14 2019-02-12 Professional Compounding Centers Of America (Pcca) Testosterone combined with anastrozole injection solutions
CN103393603B (zh) * 2013-07-22 2015-04-01 南通广泰生化制品有限公司 枸橼酸他莫昔芬颗粒
CN113133982B (zh) * 2021-03-30 2022-08-02 北京鑫开元医药科技有限公司 一种阿那曲唑片及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4543370A (en) * 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4683256A (en) * 1980-11-06 1987-07-28 Colorcon, Inc. Dry edible film coating composition, method and coating form
GB8501035D0 (en) * 1985-01-16 1985-02-20 Senior J Prostaglandins
US4832956A (en) * 1985-09-25 1989-05-23 Gerhard Gergely Disintegrating tablet and process for its preparation
US5681382A (en) * 1995-08-22 1997-10-28 Shin-Etsu Chemical Co., Ltd. Rapidly soluble coating composition and method for preparing same
US6245352B1 (en) * 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018536707A (ja) * 2015-10-30 2018-12-13 キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド エフロルニチンとスリンダクの固定用量複合製剤
US11529326B2 (en) 2015-10-30 2022-12-20 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
US11925613B2 (en) 2015-10-30 2024-03-12 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
US12350246B2 (en) 2015-10-30 2025-07-08 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation

Also Published As

Publication number Publication date
WO2003035043A3 (en) 2003-06-05
GB0125492D0 (en) 2001-12-12
EP1448171A2 (en) 2004-08-25
AU2002341145A1 (en) 2003-05-06
WO2003035043A2 (en) 2003-05-01
US20050042279A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
EP1327440B1 (en) Oral preparations with favorable disintegration characteristics
EP2331074B1 (en) Granulates, process for preparing them and pharmaceutical products containing them
EP1049467B1 (en) Celecoxib compositions
EA003217B1 (ru) Получение капсул и таблеток быстрорастворяющегося эфавиренза с использованием супердезинтеграторов
MX2012012729A (es) Formulaciones de liberacion inmediata y formas de dosis de gamma-hidroxibutirato.
CA2911212A1 (en) Cenicriviroc compositions and methods of making and using the same
KR20010086062A (ko) 고가용성 약물용 서방성 메트리스 시스템
JP2011500548A (ja) マンニトールおよび／または微結晶性セルロースを含むジボテンタン組成物
US20190046449A1 (en) A unique high-shear granulation process for improved bioavailability of rivaroxaban
WO2018095403A1 (zh) 一种吡啶酮类衍生物药物组合物及其制备方法
JP2005508971A (ja) 製剤
WO2012107090A1 (en) Granulated composition comprising tadalafil and a disintegrant
WO2003051364A1 (en) Amlopidine bezylate tablets with improved stability
WO2006035313A1 (en) Solid unit dosage forms of 5-ht1 agonist
JP6328138B2 (ja) Ｎ−［５−［２−（３，５−ジメトキシフェニル）エチル］−２ｈ−ピラゾール−３−イル］−４−［（３ｒ，５ｓ）−３，５−ジメチルピペラジン−１−イル］ベンズアミドの医薬製剤
KR100700472B1 (ko) 프로펜 함유 제약 혼합물
WO2012107092A1 (en) Pharmaceutical composition comprising tadalafil and a cyclodextrin
KR20010101521A (ko) 프로펜 및 다른 활성 화합물들의 배합물을 포함하는 제약혼합물
EP1729735B1 (en) Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
US11260055B2 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
WO2022115055A1 (en) Immediate release composition of favipiravir
NZ549097A (en) Compression-coated tablets and manufacture thereof
AU2018454263B2 (en) Dosage form containing abiraterone acetate
RU2353352C1 (ru) Твердая лекарственная форма, обладающая противовоспалительной, анальгезирующей, жаропонижающей активностью, и способ ее получения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050609

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080701